Another very successful year for the ZEISS Group

Significant revenue growth of 8.8 billion euros despite challenging geopolitical and economic conditions – EBIT at 1.6 billion euros (up 109 million euros compared to the prior year). The ZEISS Group once again significantly surpassed the strong prior-year level.

All four ZEISS segments have shown double-digit percentage growth Focused investment strategy with high expenditure on research and development (13% of revenue) Headcount rises by 10% to 38,770

OBERKOCHEN, Germany, Dec.14, 2022 /PRNewswire/ — The ZEISS Group achieved significant growth across all segments despite challenging geopolitical and economic conditions. Revenue rose by 16% to 8.8 billion euros, surpassing over 8 billion euros for the first time (prior year: 7.5 billion euros) in fiscal year 2021/22 (end of reporting period: 30 September 2022). Earnings before interest and tax (EBIT) also achieved a new peak, reaching 1.6 billion euros (prior year: 1.5 billion euros). The ZEISS Group increased orders significantly by 19% to a new record level of 10.7 billion euros (prior year: 9.0 billion euros).

“The past year was certainly very difficult and challenging in many places due to the geopolitical conditions. Nevertheless, we can look back on another successful fiscal year with a high degree of economic satisfaction,” said Dr. Karl Lamprecht, President and CEO of ZEISS. “For the first time in our history our annual revenue has exceeded the threshold of 8 billion euros. All four ZEISS segments and more than 38,000 employees have contributed to this. We are growing and at the same time investing in the future worldwide. The success shows that we are on the right track with our strategy focused on megatrends.”

Picture is available at AP Images (http://www.apimages.com)

Press contact

ZEISS Group
Jörg Nitschke, Head of Corporate Brand and Communications
Phone: +49 7364 20-3242
Email: [email protected]

Further information at www.zeiss.com

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PR Newswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, PR Newswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.